Clinical trial · no report yet · Phase 3
DREAMM-10
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- NCT06679101 ↗
- Recruiting
- GlaxoSmithKline
- 11 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma; Newly Diagnosed Multiple Myeloma
- Interventions
- Belantamab mafodotin; Lenalidomide; Dexamethasone; Daratumumab
- Arms
- Arm A: Belantamab Mafodotin + Lenalidomide + Dexamethasone · Experimental
- Arm B: Daratumumab + Lenalidomide + Dexamethasone · Active comparator
- Enrollment
- 520 (estimated)
- Primary outcomes
- PFS
- Number of Participants Achieving MRD Negative Status
- Sponsor
- GlaxoSmithKline
- Start
- Dec 16, 2024
- Primary completion
- Apr 28, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT06679101 · updated Apr 22, 2026